Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA;
Clin Chem. 2013 Nov;59(11):1657-67. doi: 10.1373/clinchem.2012.199133. Epub 2013 Jul 29.
Rigorous studies are necessary to demonstrate suitability of metabolomics platforms to profile metabolites in archived plasma within epidemiologic studies of human disease, for which attenuation of effect estimates due to measurement error is a key concern.
Using a liquid chromatography-tandem mass spectrometry platform, we quantified 257 metabolites from archived plasma to evaluate metabolite interassay reproducibility, reproducibility with delayed processing, and within-person reproducibility over time. Interassay reproducibility was assessed with CVs from 60 duplicate plasma samples donated by participants in the Nurses' Health Study and Health Professionals Follow-up Study, and 20 QC pool plasma replicates. Metabolite reproducibility over a 24- to 48-h processing delay (n = 48 samples) and within-person reproducibility over 1-2 years (n = 80 samples) were assessed using Spearman and intraclass correlation coefficients (ICCs).
CVs were <20% for 92% of metabolites and generally were similar by plasma anticoagulant type (heparin or EDTA) and fasting time. Approximately 75% of metabolites were reproducible over delays in processing of blood samples (Spearman correlation or ICC ≥ 0.75, comparing immediate and 24-h delayed processing). Carbohydrates and purine/pyrimidine derivatives were most adversely affected by the processing delay. Ninety percent of metabolites were reproducible over 1-2 years within individuals (Spearman correlation or ICC ≥ 0.4).
For potential use in epidemiologic studies, the majority of plasma metabolites had low CVs and were reproducible over a 24-h processing delay and within individuals over 1-2 years. Certain metabolites, such as carbohydrates and purine/pyrimidine derivatives, may be challenging to evaluate if samples have delayed processing.
为了在人类疾病的流行病学研究中证明代谢组学平台适合分析存档血浆中的代谢物,需要进行严格的研究,因为由于测量误差导致的效应估计值衰减是一个关键问题。
我们使用液相色谱-串联质谱平台从存档血浆中定量了 257 种代谢物,以评估代谢物的测定内重复性、延迟处理后的重复性以及个体内随时间的重复性。通过来自参加护士健康研究和健康专业人员随访研究的 60 个重复血浆样本和 20 个 QC 池血浆重复的 CV 评估测定内重复性。通过 Spearman 和组内相关系数(ICC)评估 24-48 小时处理延迟(n=48 个样本)和 1-2 年内个体内的重复性(n=80 个样本)。
CVs<20%的代谢物占 92%,并且通常与血浆抗凝剂类型(肝素或 EDTA)和禁食时间相似。大约 75%的代谢物在血液样本处理延迟时具有可重复性(Spearman 相关性或 ICC≥0.75,比较即时和 24 小时延迟处理)。碳水化合物和嘌呤/嘧啶衍生物受处理延迟的影响最大。90%的代谢物在个体内 1-2 年内具有可重复性(Spearman 相关性或 ICC≥0.4)。
对于在流行病学研究中的潜在应用,大多数血浆代谢物具有低 CVs,并且在 24 小时处理延迟和个体内 1-2 年内具有可重复性。如果样本处理延迟,某些代谢物(如碳水化合物和嘌呤/嘧啶衍生物)可能难以评估。